Schwietert M, Battegay M
Medizinische Universitäts-Poliklinik, Kantonsspital Basel.
Dtsch Med Wochenschr. 1999 Jan 22;124(3):45-8. doi: 10.1055/s-2007-1024241.
A 30-year-old man with a known HIV infection for 7 years presented for treatment with antiretroviral drugs. He was known to have had herpes zoster, oral hairy leukoplakia and recurrent Candida stomatitis, but was otherwise without symptoms.
The CD4 lymphocyte count was 19 cells/mm3 and there were 41,000 HIV-RNA copies/ml.
DIAGNOSIS, TREATMENT AND COURSE: The HIV infection was in CDC stage B3, indicating the need for combined antiretroviral treatment. A week after starting stavudine, saquinavir and ritonavir he had to be admitted because of nausea and vomiting, colicky abdominal pain, diarrhea, fever up to 39 degrees C and a rise of C-reactive protein to 207 mg/dl. Bacteriological examination of feces and biopsy of an enlarged retroperitoneal lymph node revealed atypical mycobacteria. Antituberculosis treatment was started. The CD4 cell count rose to 56/mm3 and the viral count fell to 11,000/ml. Each time after initiating a different antiviral regimen the symptoms recurred.
This case illustrates an atypical manifestation of on opportunistic infection: during combined antiviral treatment the CD4 cell count rose and thus precipitated an heretofore subclinical mycobacterial infection with focal lymphadenitis. If, on starting antiretroviral treatment at a late HIV stage, new symptoms develop within 1-3 weeks, one should consider drug-induced side effects or the onset of an opportunistic infection that has become manifest as the result of an improved immunological state.
一名30岁男性,已知感染HIV 7年,前来接受抗逆转录病毒药物治疗。他曾患带状疱疹、口腔毛状白斑和复发性念珠菌性口炎,但除此之外并无其他症状。
CD4淋巴细胞计数为19个/立方毫米,HIV-RNA拷贝数为41,000/毫升。
诊断、治疗与病程:HIV感染处于美国疾病控制与预防中心(CDC)的B3期,表明需要进行联合抗逆转录病毒治疗。开始使用司他夫定、沙奎那韦和利托那韦一周后,他因恶心、呕吐、绞痛性腹痛、腹泻、体温高达39摄氏度以及C反应蛋白升至207毫克/分升而入院。粪便细菌学检查和肿大的腹膜后淋巴结活检显示非典型分枝杆菌。开始抗结核治疗。CD4细胞计数升至56/立方毫米,病毒载量降至11,000/毫升。每次更换不同的抗病毒治疗方案后,症状都会复发。
该病例说明了一种机会性感染的非典型表现:在联合抗病毒治疗期间,CD4细胞计数上升,从而引发了此前亚临床的分枝杆菌感染并伴有局灶性淋巴结炎。如果在HIV晚期开始抗逆转录病毒治疗时,在1 - 3周内出现新症状,应考虑药物引起的副作用或因免疫状态改善而显现的机会性感染的发生。